DiaMedica Q3 net loss $8.6M; ReMEDy2 trial at 50% enrollment

DiaMedica Therapeutics Inc.

Net loss $8.6M in Q3 2025, up from $6.3M a year ago; R&D expense $6.4M, up from $5.0M.
Cash and short-term investments $55.3M as of Sept 30, 2025; funded into 2H 2027.
ReMEDy2 Phase 2/3 AIS trial enrollment nearing 50% of 200-patient interim target.
Preeclampsia IST Part 1a expansion cohort enrolling; Part 3 fetal growth restriction screening starting soon.
Pre-IND meeting with FDA on DM199 for preeclampsia held; update after minutes received.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.